YMAB

Y-mAbs Therapeutics, Inc. (YMAB) | Rumor.io

Y-mAbs Therapeutics

YMAB

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about YMAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 6

Y-mAbs Therapeutics, Inc. (YMAB) was acquired by SERB Pharmaceuticals for $412M at a 105% premium.
HC Wainwright & Co. adjusted their rating on YMAB to Neutral with a target price of $8.6.
Canaccord Genuity adjusted their rating on YMAB to Hold with a target price of $8.6, down from $26.

Generated by AI

Sentiment

Of the messages about YMAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.77% +23.91
Bearish	—	—	—	9.23% -23.91

Bullish· Aug 5

$YMAB is experiencing a strong breakout, with a surge in volume and a rise in the Relative Strength Index (RSI).
The company has a relatively low float of 39 million, which could contribute to its volatility and potential for a significant price movement.
$YMAB is showing high relative strength, indicating that it is outperforming the market and could be a good candidate for further gains.

Bearish· Mar 31

$YMAB's recent earnings report showed a negative EBITA of $129 million.
The stock's trendline has been broken, and it needs to hold the gap of $5.55 from the weekly chart.
The company's cash reserves are dwindling, with only 2 years of funds remaining, increasing the likelihood of a significant price drop.

Generated by AI

Topics

Of the messages about YMAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.1%
Announcements	—	—	—	67.03%
Controversies	—	—	—	10.99%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	20.88%

Analysts· Oct 31

Y-mAbs Therapeutics was downgraded to Underweight from Neutral at JPMorgan.
Morgan Stanley lowered the price target for Y-mAbs Therapeutics to $8 from $17.
Wedbush downgraded Y-mAbs Therapeutics to Neutral and set a price target of $6.

Announcements· May 9

Y-mAbs Therapeutics, Inc. reported Q1 2023 financial results, with a loss of $0.15 per share beating estimates and revenue of $20.25M beating estimates by $4.7M.
The company's stock price surged 21% after hours following the earnings beat.
Y-mAbs Therapeutics' Q1 revenue and EPS exceeded market expectations, with revenue of $20.25M beating estimates by $4.7M and EPS of -$0.15 beating estimates by $0.17.

Technical Analysis· Mar 31

The stock has broken through $5, and its ability to hold support and continue higher lows is being watched.
A downtrend line for the stock is identified, and a potential second leg up is being considered if the current level holds.
The stock's weekly chart shows a gap entry at $5.55, and a broken trendline is seen, with a gap that needs to hold according to the author.

Generated by AI

Community

Of the messages about YMAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	28.9%
Newcomers	—	—	—	71.1%

Regulars· May 15

Y-mAbs Therapeutics' price target has been increased to $12.00 by Bank of America analysts.
Bank of America Securities has maintained a neutral rating on Y-mAbs Therapeutics and raised its price target from $6 to $12.
Y-mAbs Therapeutics' stock price has experienced significant increases, with a 10.53% and 12.18% rise in the last 20 minutes.

Newcomers· May 9

New traders are learning that it's possible to start small and build a bankroll through smart trades, citing a success story with Susan.
The $YMAB stock has surged 34.42% today, with a notable increase in volume, but the question remains whether this upward trend will continue.
A Canaccord Genuity analyst has raised the price target for Y-mAbs Therapeutics to $21 from $18, maintaining a Buy rating.

Generated by AI

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of John W. LaRocca, Esq. to its Board of Directors. Mr. LaRocca will also serve as a member of the Company's Audit Committee.Mr. LaRocca is a three-decade biopharmaceutical industry executive...

2mo agofinance.yahoo.com

Also Discussed

Investors talking about YMAB also mention

#	Name	Attention
1	Bicycle Therapeutics plc - ADRBCYC	0%0
2	MRTX - Mirati Therapeutics, Inc.	——
3	Alector Inc.ALEC	0%new
4	Zymeworks Inc.ZYME	0%0
5	ATXS - Astria Therapeutics, Inc.	——
6	IGMS - IGM Biosciences, Inc.	——
7	GRTS - Gritstone bio, Inc.	——
8	Nuvectis Pharma, Inc.NVCT	0%0
9	FUSN - Fusion Pharmaceuticals Inc.	——
10	DCPH - Deciphera Pharmaceuticals, Inc.	——